TEVA PHARMACEUTICAL INDUSTRIES SPON ADS EACH REP 1 ORD SHS
Teva Pharmaceutical Industries Ltd (TEVA) is a global pharmaceutical company best known for its large generics business and select specialty medicines. With a market capitalisation near $22 billion, Teva supplies a broad range of off‑patent medicines alongside branded treatments in areas such as central nervous system disorders. The company has undergone significant restructuring in recent years to cut costs, manage debt and refocus R&D. Key investor considerations include pricing pressure in generics, patent cliffs for older products, ongoing litigation and the balance sheet after past acquisitions. At the same time, scale in manufacturing, a diversified product mix and potential upside from speciality drugs or successful pipeline assets can support recovery. Investors should weigh Teva’s income statement trends, cash generation, debt reduction progress and the regulatory environment. This is general information for educational purposes only and not personalised investment advice; stock prices can fall as well as rise.
Why It's Moving
Wall Street Sees 35% Upside for Teva as Analyst Consensus Turns Bullish on Pharmaceutical Turnaround
- Analyst consensus flipped to 'Strong Buy' with 9 of 10 recent ratings on the positive side, supported by an average 12-month price target of $22.88 representing 35% upside potential
- Multiple Wall Street firms have raised targets into the $29–$31 range, signaling confidence in upcoming catalysts and margin expansion as the company executes its strategic initiatives
- Recent quarterly earnings beat expectations with results outpacing forecasts, reigniting investor interest in a stock that traded in a depressed range earlier in the year
Wall Street Sees 35% Upside for Teva as Analyst Consensus Turns Bullish on Pharmaceutical Turnaround
- Analyst consensus flipped to 'Strong Buy' with 9 of 10 recent ratings on the positive side, supported by an average 12-month price target of $22.88 representing 35% upside potential
- Multiple Wall Street firms have raised targets into the $29–$31 range, signaling confidence in upcoming catalysts and margin expansion as the company executes its strategic initiatives
- Recent quarterly earnings beat expectations with results outpacing forecasts, reigniting investor interest in a stock that traded in a depressed range earlier in the year
When is the next earnings date for TEVA PHARMACEUTICAL INDUSTRIES SPON ADS EACH REP 1 ORD SHS (TEVA)?
Teva Pharmaceutical Industries (TEVA) is scheduled to report its Q1 2026 earnings on April 29, 2026, before the market opens. This release covers the quarter ended March 31, 2026, with analysts anticipating EPS of approximately $0.52 and revenue around $3.85 billion. A conference call is set for 8:00 AM ET following the release.**
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Teva's stock with a target price of $34.71, indicating growth potential.
Financial Health
Teva is generating solid revenue and cash flow, with healthy profit margins supporting its financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
APELLIS PHARMACEUTICALS INC
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
Baskets Featuring TEVA
Domestic Pharma Tariffs: What's Next for Investors
The U.S. government has imposed a 100% tariff on pharmaceuticals from companies lacking domestic manufacturing, aiming to reshore production. This policy creates a significant advantage for U.S.-based pharmaceutical companies and their supply chains, which are poised for growth as reliance on imports decreases.
Published: September 26, 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: August 4, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Volume & Scale
Teva’s large manufacturing footprint drives cost advantages in generics, which can support margins — though pricing pressure and competition remain important caveats.
Speciality Pipeline Focus
Selective branded assets and R&D in areas like CNS could offer upside if successful, but development outcomes and regulatory hurdles create uncertainty.
Balance Sheet Watch
Investors often focus on debt reduction and cash flow recovery; improvements can strengthen prospects, while unresolved liabilities can limit flexibility.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
